Navigation Links
PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
Date:1/9/2008

BOSTON, Jan. 9 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, today announced that Eduard E. Holdener, M.D., formerly Head of Global Pharmaceutical Development at F. Hoffmann-La Roche, Ltd., has been elected to its Board of Directors.

Dr. Holdener was recently appointed to the role of non-executive Chairman of NovImmune. The biotechnology Company develops new therapeutic agents in the field of immune-related disorders and inflammation.

"With 22 years of biopharmaceutical industry experience, which has included managing global operations and overseeing global drug development during the past nine years for a major pharmaceutical company, Dr. Holdener will be an excellent addition to PAREXEL and our Board of Directors," said Josef von Rickenbach, PAREXEL's Chairman and Chief Executive Officer. "Our clients and shareholders will certainly benefit from the extensive expertise Dr. Holdener brings to the Company as we continue to be a premier provider to the biopharmaceutical industry in the development and commercialization of important new therapies worldwide."

In his former role as Global Head of Pharmaceutical Drug Development at Roche, Dr. Holdener successfully led a worldwide development organization, which was instrumental in receiving approvals for key oncology, virology, rheumatology, and anemia drugs in many related indications. He also served as the Company's Chief Medical Officer. During his career with the Company, he helped to establish and expand the oncology therapeutic area, and was presented with the Roche Research and Development Prize in the early 90's. Dr. Holdener led the Company's development operations in Japan for several years in the late 90's, and was instrumental during the Roche/Chugai merger at the beginning of this millennium. He was also responsible for establishing a new development center in Shanghai, China in 2007. Dr. Holdener served on several executive committees at the departmental, divisional, and corporate levels, which focused particularly on portfolio strategies and functional excellence. Prior to joining Roche, Dr. Holdener held positions as a clinical oncologist in hospital settings and academic institutions, both in Switzerland and the United States.

Dr. Holdener received his Medical Degree from the University of Zurich and Basel Medical School in Switzerland, and completed his fellowship in Oncology at the University of Kansas Medical Center in the United States. He is Board Certified in Internal Medicine and Oncology/Hematology in Switzerland.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has approximately 7,000 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contact for investors and analysts:

Jill Baker

Vice President, Investor Relations

Tel: 781-434-4118

Email: Jill.Baker@PAREXEL.com

Contact for media:

Jennifer Baird

Director of Public Relations

Tel: 781-434-4409

Email: Jennifer.Baird@PAREXEL.com


'/>"/>
SOURCE PAREXEL
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
3. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
4. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
5. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
6. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
7. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
8. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
9. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
10. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):